Groowe / Newsroom / ADAG

⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

ADAG News

Adagene Inc. American Depositary Shares

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

globenewswire.com Oct 31, 2025 12:01 PM